Beta Drugs Reports Strong H1 FY27 Performance with 45% PAT Growth
Beta Drugs Ltd · Transcript · 28 Oct 2026, 10:27 pm
Beta Drugs Reports Strong H1 FY27 Performance with 45% PAT Growth Beta Drugs posted 29.2% YoY revenue growth for H1 FY27, with PAT rising ~45% YoY to INR34 crores and EBITDA margins at 23.18%. Management noted zero material impact from NPPA trade margin capping. Nivian Lifesciences grew 75% YoY to INR31 crores, while the API segment expanded 29% YoY, supported by an upcoming intermediate plant operational by Jan'27. Management reaffirmed medium-term revenue growth guidance of 20%–25% with 23%–24% sustained EBITDA margins, targeting INR150 crores in own-brand sales and INR90–100 crores in exports for FY27.
Original exchange filing (PDF)
More announcements from Beta Drugs Ltd
- BETA DRUGS LIMITED has informed the Exchange about Board Meeting to be held on 19-Nov-2026 to consider Other business. · 16 Nov 2026
- To consider other business matters · 16 Nov 2026
- Monitoring Agency Report as on 30th September, 2026 · 12 Nov 2026
- Beta Drugs Limited has informed the Exchange about Link of Recording · 22 Oct 2026
- Beta Drugs Limited has informed the Exchange about statement of deviation(s) or variation(s) under Reg. 32 · 22 Oct 2026
- Beta Drugs Limited has informed the Exchange about Presentation · 22 Oct 2026
- Beta Drugs Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 22 Oct 2026
- Beta Drugs Limited has informed the Exchange about Schedule of meet · 22 Oct 2026
